Myasthenia gravis: immunological mechanisms and immunotherapy.
This review of the immunological aspects of myasthenia gravis and the immunotherapy of the disease emphasizes the current state of knowledge of the immunological events at the neuromuscular junction, and the immunoregulatory abnormalities noted in myasthenic patients. The treatment modalities available to the clinician are discussed in an attempt to provide information that will allow for a rational approach to therapy.
Lewis
R A
RA
Department of Neurology, Wayne State University School of Medicine, Detroit, MI 48201, USA.
Selwa
J F
JF
Lisak
R P
RP
D001327:Autoimmune Diseases / Q000276:immunology* / Q000628:therapy; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007167:Immunotherapy; D016131:Lymphocyte Subsets / Q000276:immunology; D008297:Male; D009157:Myasthenia Gravis / Q000276:immunology* / Q000628:therapy; D009469:Neuromuscular Junction / Q000276:immunology; D010951:Plasma Exchange; D011950:Receptors, Cholinergic / Q000276:immunology; D013934:Thymectomy; D013945:Thymoma / Q000150:complications / Q000601:surgery; D013950:Thymus Gland / Q000473:pathology; D013953:Thymus Neoplasms / Q000150:complications / Q000601:surgery
D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents; D011950:Receptors, Cholinergic